WIN-Partners Co., Ltd. (JP:3183)
:3183
Top Page
WIN-Partners Co., Ltd.
(3183)
Select Model
Select Model
Rating:74Outperform
Price Target:
¥1,682.00
▲(26.85% Upside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by strong financial stability (notably a debt-free balance sheet and steady profitability). Technicals add support with a positive trend and momentum, though some near-term froth is indicated by a high stochastic reading. Valuation is balanced, with a reasonable P/E and a strong dividend yield.
Positive Factors
Debt-free balance sheet
Zero reported debt materially reduces financial risk and interest-rate sensitivity, giving the company durable flexibility. A debt-free structure supports reliable capital allocation choices, preserves dividend capacity and enables opportunistic investments or M&A without raising leverage over the medium term.
Negative Factors
Recent revenue contraction
Top-line turned slightly negative in 2025 after prior expansion, which risks undermining operating leverage and future margin expansion. Persistent or recurring revenue weakness would limit internal funding for growth initiatives, constrain hiring and investments, and reduce long-term earnings visibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially reduces financial risk and interest-rate sensitivity, giving the company durable flexibility. A debt-free structure supports reliable capital allocation choices, preserves dividend capacity and enables opportunistic investments or M&A without raising leverage over the medium term.
Read all positive factors
WIN-Partners Co., Ltd. (3183) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥37.92B
Dividend Yield3.97%
Average Volume (3M)11.73K
Price to Earnings (P/E)18.1
Beta (1Y)0.73
Revenue Growth6.63%
EPS Growth11.04%
CountryJP
Employees629
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)18.57
Shares Outstanding30,503,310
10 Day Avg. Volume13,600
30 Day Avg. Volume11,726
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)1.58
Price to Sales (P/S)0.47
P/FCF Ratio23.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
WIN-Partners Co., Ltd. Business Overview & Revenue Model
Company Description
WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular u...
How the Company Makes Money
WIN-Partners Co., Ltd. generates revenue primarily through the sale of medical equipment and devices to healthcare institutions such as hospitals and clinics. The company earns money by acting as a distributor, sourcing products from various manuf...
WIN-Partners Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
88
Very Positive
Cash Flow
61
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.89B | 81.41B | 77.06B | 70.85B | 66.39B | 62.12B |
| Gross Profit | 10.10B | 9.89B | 9.53B | 8.66B | 8.52B | 7.74B |
| EBITDA | 3.17B | 3.10B | 2.92B | 3.11B | 2.82B | 2.45B |
| Net Income | 2.10B | 2.02B | 1.84B | 2.05B | 1.83B | 1.54B |
Balance Sheet | ||||||
| Total Assets | 46.98B | 46.65B | 47.75B | 43.91B | 41.59B | 40.21B |
| Cash, Cash Equivalents and Short-Term Investments | 16.83B | 16.21B | 18.16B | 16.77B | 15.57B | 17.12B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 24.96B | 22.58B | 24.37B | 21.12B | 19.86B | 19.07B |
| Stockholders Equity | 22.02B | 24.07B | 23.39B | 22.78B | 21.72B | 21.14B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.59B | 2.54B | -525.17M | -136.90M | 673.91M |
| Operating Cash Flow | 0.00 | 2.06B | 3.04B | 445.15M | 2.62B | 1.85B |
| Investing Cash Flow | 0.00 | -2.17B | -219.47M | 1.92B | -2.89B | -1.28B |
| Financing Cash Flow | 0.00 | -1.83B | -1.45B | -1.16B | -1.28B | -947.37M |
WIN-Partners Co., Ltd. Technical Analysis
Negative
1326.00
Price Trends
1362.89
Negative
1313.10
Positive
1294.71
Positive
Market Momentum
-11.38
Positive
37.70
Neutral
4.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3183, the sentiment is Negative. The current price of 1326 is below the 20-day moving average (MA) of 1375.77, below the 50-day MA of 1362.89, and above the 200-day MA of 1294.71, indicating a neutral trend. The MACD of -11.38 indicates Positive momentum. The RSI at 37.70 is Neutral, neither overbought nor oversold. The STOCH value of 4.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3183.
WIN-Partners Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥37.92B | 18.06 | ― | 3.97% | 6.63% | 11.04% | |
63 Neutral | ¥15.06B | 14.76 | ― | 3.12% | 3.59% | -163.08% | |
62 Neutral | ¥44.54B | 10.69 | ― | 0.91% | 15.77% | -50.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥68.74B | 77.03 | 5.76% | ― | 31.95% | -40.95% | |
45 Neutral | ¥6.66B | 33.86 | ― | 1.41% | 18.03% | -11.68% |
* Healthcare Sector Average
JP:3183
WIN-Partners Co., Ltd.
1,321.00
197.58
17.59%
JP:4480
Medley
2,100.00
-817.00
-28.01%
JP:7061
Japan Hospice Holdings Inc.
790.00
-524.18
-39.89%
JP:7071
Amvis Holdings.Inc.
453.00
44.70
10.95%
JP:7600
Japan Medical Dynamic Marketing, Inc.
572.00
112.89
24.59%
WIN-Partners Co., Ltd. Corporate Events
WIN-Partners Raises Year-End Dividend Forecast for Fiscal 2026
Feb 9, 2026
WIN-Partners Co., Ltd. has revised its dividend forecast for the fiscal year ending March 2026, announcing an increase in the planned year-end dividend from ¥53.00 to ¥54.00 per share, bringing the total annual dividend to ¥54.00. T...
WIN-Partners Launches Share Buyback to Boost Capital Efficiency and Shareholder Returns
Feb 9, 2026
WIN-Partners Co., Ltd. has approved a share buyback program, authorizing the repurchase of up to 290,000 shares of common stock, equivalent to about 1.0% of its outstanding shares excluding treasury stock. The buyback, capped at 400 million yen an...
WIN-Partners Lifts Dividend as Nine-Month Profit Rises Nearly 9%
Feb 9, 2026
WIN-Partners Co., Ltd. reported consolidated net sales of ¥66.28 billion for the nine months ended December 31, 2025, up 9.7% year on year, with operating profit rising 8.0% to ¥2.23 billion and profit attributable to owners of parent in...
WIN-Partners Expands Hokkaido Footprint With Acquisition of Plusten Medical
Dec 26, 2025
WIN-Partners has announced that its consolidated subsidiary WIN International will acquire all shares of Plusten Medical Co., Ltd., a medical equipment sales and service company based in Hakodate, Hokkaido. The all-cash acquisition, effective Janu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.